97 related articles for article (PubMed ID: 23692562)
1. HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules.
Hofström C; Altai M; Honarvar H; Strand J; Malmberg J; Hosseinimehr SJ; Orlova A; Gräslund T; Tolmachev V
J Med Chem; 2013 Jun; 56(12):4966-74. PubMed ID: 23692562
[TBL] [Abstract][Full Text] [Related]
2. HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation.
Tolmachev V; Hofström C; Malmberg J; Ahlgren S; Hosseinimehr SJ; Sandström M; Abrahmsén L; Orlova A; Gräslund T
Bioconjug Chem; 2010 Nov; 21(11):2013-22. PubMed ID: 20964447
[TBL] [Abstract][Full Text] [Related]
3. Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I.
Hofstrom C; Orlova A; Altai M; Wangsell F; Graslund T; Tolmachev V
J Med Chem; 2011 Jun; 54(11):3817-26. PubMed ID: 21524142
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus.
Lindberg H; Hofström C; Altai M; Honorvar H; Wållberg H; Orlova A; Ståhl S; Gräslund T; Tolmachev V
Tumour Biol; 2012 Jun; 33(3):641-51. PubMed ID: 22249974
[TBL] [Abstract][Full Text] [Related]
5. Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules.
Ekblad T; Orlova A; Feldwisch J; Wennborg A; Karlström AE; Tolmachev V
Bioorg Med Chem Lett; 2009 Jul; 19(14):3912-4. PubMed ID: 19364646
[TBL] [Abstract][Full Text] [Related]
6. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.
Tran TA; Ekblad T; Orlova A; Sandström M; Feldwisch J; Wennborg A; Abrahmsén L; Tolmachev V; Eriksson Karlström A
Bioconjug Chem; 2008 Dec; 19(12):2568-76. PubMed ID: 19035668
[TBL] [Abstract][Full Text] [Related]
7. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.
Altai M; Wållberg H; Orlova A; Rosestedt M; Hosseinimehr SJ; Tolmachev V; Ståhl S
Amino Acids; 2012 May; 42(5):1975-85. PubMed ID: 21573874
[TBL] [Abstract][Full Text] [Related]
8. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
[TBL] [Abstract][Full Text] [Related]
9. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
10. Optimal composition and position of histidine-containing tags improves biodistribution of
Vorobyeva A; Schulga A; Konovalova E; Güler R; Löfblom J; Sandström M; Garousi J; Chernov V; Bragina O; Orlova A; Tolmachev V; Deyev SM
Sci Rep; 2019 Jun; 9(1):9405. PubMed ID: 31253840
[TBL] [Abstract][Full Text] [Related]
11. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
12. Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine.
Ahlgren S; Andersson K; Tolmachev V
Nucl Med Biol; 2010 Jul; 37(5):539-46. PubMed ID: 20610158
[TBL] [Abstract][Full Text] [Related]
13. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
[TBL] [Abstract][Full Text] [Related]
14. Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule.
Orlova A; Malm M; Rosestedt M; Varasteh Z; Andersson K; Selvaraju RK; Altai M; Honarvar H; Strand J; Ståhl S; Tolmachev V; Löfblom J
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1450-9. PubMed ID: 24622956
[TBL] [Abstract][Full Text] [Related]
15. Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.
Wållberg H; Löfdahl PK; Tschapalda K; Uhlén M; Tolmachev V; Nygren PK; Ståhl S
Protein Expr Purif; 2011 Mar; 76(1):127-35. PubMed ID: 21029777
[TBL] [Abstract][Full Text] [Related]
16. Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.
Ekblad T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsén L; Wennborg A; Karlström AE; Tolmachev V
Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2245-55. PubMed ID: 18594815
[TBL] [Abstract][Full Text] [Related]
17. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
